Yoshimi Endo Greer, M.D., Ph.D.
Dr. Yoshimi E. Greer has extensive experience in cell biology, molecular biology, biochemistry and oncology. Her recent research focuses are 1) TRAIL-induced cell death, and 2) mitochondria in cancer. She is exploring potential clinical applications utilizing those mechanisms in cancer treatment. One of her studies has recently contributed to launch clinical trials in breast and endometrial cancers at NCI. She is always seeking exciting collaborations across the NIH campus to promote science discovery in cancer field.
- Oncotarget. 9: 18454-18479, 2018. [ Journal Article ]
- Science Signaling. 9: 415, 2016. [ Journal Article ]
The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl..Breast Cancer Res Treat. 155(2): 235-51, 2016. [ Journal Article ]
- Oncoscience. 2(2): 75-6, 2015. [ Journal Article ]
Lack of Casein Kinase 1 Delta Promotes Genomic Instability - The Accumulation of DNA Damage and Down-Regulation of Checkpoint Kinase 1..PLoS One. 12(1): e0170903, 2017. [ Journal Article ]
Dr. Yoshimi E. Greer obtained her M.D. in 1994 from Tohoku University School of Medicine in Sendai, Japan. She conducted her clinical residency training in internal medicine for 5 years. In 1999, Dr. Greer received Ph.D. in renal physiology the Graduate School of Tohoku University. Her dissertation research focused on the role of the Angiotensin II receptor inhibitor on micro-hemodynamics in kidney.
In 1998, Dr. Greer joined Dr. Josephine P. Briggs' lab at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) as a postdoctoral fellow and studied the transcriptional regulatory mechanism of Cyclooxygenase (COX)-2. In 2001, she joined Dr. Jeff Rubin's lab at the NCI-CCR, and she studied the molecular mechanism of Wnt3a-dependent cell motility in mammalian cells. In 2004, Dr. Greer joined Georgetown University Medical School as a research instructor (junior faculty) and studied the transcriptional mechanism of VE-cadherin that is involved with retinoic acid-mediated trans-differentiation of breast cancer cells.
In 2006, Dr. Greer returned to NCI as a research fellow, and continued her Wnt signal research. She discovered the molecular mechanisms how Wnt-3a stimulates neurite outgrowth in Ewing tumor cells. In 2009, she became a staff scientist in the Laboratory of Cellular and Molecular Biology, CCR. She investigated the functional role of casein kinase 1 delta, a critical kinase involved in Wnt signaling, and identified that CK1delta plays a role in neurite outgrowth, primary ciliogenesis, as well as DNA damage control.
In 2014, she joined Dr. Stan Lipkowitz’s lab to explore her great interest in oncology. Her current research focus is 1) to develop breast cancer treatment strategies utilizing TRAIL/Death Receptor, 2) to investigate the role of mitochondria in cancer as a therapeutic target.